# A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

> **NCT04982276** · PHASE1,PHASE2 · RECRUITING · sponsor: **Akeso** · enrollment: 138 (estimated)

## Conditions studied

- Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

## Interventions

- **BIOLOGICAL:** AK109
- **DRUG:** paclitaxel
- **DRUG:** paclitaxel
- **BIOLOGICAL:** AK104

## Key facts

- **NCT ID:** NCT04982276
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-23
- **Primary completion:** 2025-12-30
- **Final completion:** 2027-01-31
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04982276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04982276, "A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04982276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*